Valve Design and Paravalvular Aortic Regurgitation: New Insights from the French Registry
Transcatheter aortic valve replacement (TAVR) has emerged as an important treatment option for patients with severe aortic stenosis (AS) who are either inoperable or at high risk for surgical aortic valve replacement (SAVR). Currently two valves are approved by FDA for inoperable patients whereas 9 valves have received CE mark in Europe for TAVR.
In a randomized trial of a balloon-expandable (BE) valve TAVR was found to be non-inferior to surgical AVR (SAVR) for the primary end point of death, but markedly inferior from the standpoint of AR.1 Data from observational studies suggest even higher rates of AR after self-expandable (SE) valve implantation.1 Several studies have reported increased mortality in patients with AR after TAVR making it a clinically important end-point. In the current issue of Circulation Van Belle et al. present an analysis from French Registry which provides support for the previously published data while offering some new important insights.
- Received February 7, 2014.
- Accepted February 11, 2014.